Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
11°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karyopharm Therapeut
(NQ:
KPTI
)
0.8525
-0.0233 (-2.66%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Karyopharm Therapeut
< Previous
1
2
3
4
5
6
Next >
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
November 05, 2024
KPTI earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Monday's After-Market Session
September 30, 2024
Via
Benzinga
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
August 06, 2024
KPTI earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
May 23, 2024
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.
Via
InvestorPlace
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Karyopharm Therapeutics's Earnings: A Preview
February 28, 2024
Via
Benzinga
Earnings Preview For Karyopharm Therapeutics
November 01, 2023
Via
Benzinga
6 Analysts Have This to Say About Karyopharm Therapeutics
August 03, 2023
Via
Benzinga
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
May 08, 2024
KPTI earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
February 29, 2024
KPTI earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
February 25, 2024
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 06, 2024
Via
Benzinga
4 Analysts Have This to Say About Karyopharm Therapeutics
July 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via
Benzinga
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
November 02, 2023
KPTI earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks That Hit 52-Week Lows On Wednesday
August 30, 2023
On Wednesday, 59 companies achieved new lows for the year.
Via
Benzinga
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript
August 02, 2023
KPTI earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation
July 26, 2023
Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 18, 2023
During Tuesday's trading, 46 companies set new 52-week lows.
Via
Benzinga
CMG Stock Alert: Chipotle Announces International Expansion Plan
July 18, 2023
Chipotle Mexican Grill (CMG) stock is in the news Tuesday after the restaurant chain announced plans for an international expansion.
Via
InvestorPlace
Why Are Karyopharm Therapeutics Shares Gaining Today?
July 18, 2023
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 18, 2023
Via
Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
July 18, 2023
CEL-SCI (CVM) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering.
Via
InvestorPlace
Why Is Masimo (MASI) Stock Down 30% Today?
July 18, 2023
Masimo (MASI) stock is taking a beating on Tuesday after the patient monitoring tech company released preliminary earnings for Q2 2023.
Via
InvestorPlace
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
July 18, 2023
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...
Via
Benzinga
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
July 18, 2023
Karyopharm Therapeutics (KPTI) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.